416860-02-1

Basic information

• Product Name: N-[2-(4-bromoacetyl-phenyl)-ethyl]-acetamide
• Synonyms: N-[2-(4-bromoacetyl-phenyl)-ethyl]-acetamide
• CAS NO: 416860-02-1
• Molecular Weight: 284.153
• Mol File: 416860-02-1.mol

Chemical Properties

• CAS DataBase Reference: N-[2-(4-bromoacetyl-phenyl)-ethyl]-acetamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-[2-(4-bromoacetyl-phenyl)-ethyl]-acetamide(416860-02-1)
• EPA Substance Registry System: N-[2-(4-bromoacetyl-phenyl)-ethyl]-acetamide(416860-02-1)

Safety Data

• Hazardous Substances Data: 416860-02-1(Hazardous Substances Data)

Upstream product

• 23279-64-3 N-[2-(4-acetylphenyl)ethyl]acetamide 

Relevant articles and documents

Discovery of potent and orally bioavailable heterocycle-based β3-adrenergic receptor agonists, potential therapeutics for the treatment of obesity

A novel series of heterocycle-based analogs were prepared and evaluated for their in vitro and in vivo biological activity as human β3-adrenergic receptor (AR) agonists. Several analogs demonstrated potent agonist activity at the β3-

Bita3 adrenergic receptor agonists and uses thereof

The instant invention provides β3 adrenergic receptor agonists of structural Formula (I), the stereoisomers and prodrugs thereof, and the pharmaceutically acceptable salts of the compounds, stereoisomers and prodrugs, wherein Ar, R, R1, R2, R3, R4, R5, R6, R7, R8, X, and Y, are as defined herein. The invention further provides intermediates useful in the preparation of the compounds of Formula (I), to combinations of the compounds of Formula (I), the stereoisomers and prodrugs thereof, and the pharmaceutically acceptable salts of the compounds, stereoisomers and prodrugs, with anti-obesity agents; to pharmaceutical compositions comprising the compounds of Formula (I), the stereoisomers and prodrugs thereof, and the pharmaceutically acceptable salts of the compounds, stereoisomers and prodrugs, or pharmaceutical compositions comprising the compounds of Formula (I), the stereoisomers and prodrugs thereof, and the pharmaceutically acceptable salts of the compounds, stereoisomers and prodrugs, and anti-obesity agents; and methods of treating β3 adrenergic receptor-mediated diseases, conditions, or disorders in a mammal which methods comprise administering to the mammal an effective amount of a compound of Formula (I), a stereoisomer or prodrug thereof, or a pharmaceutical composition thereof; or a combination of a compound of Formula (I), a pharmaceutically acceptable salt of the compound, stereoisomer, or prodrug, and an anti-obesity agent, or a pharmaceutical composition thereof.